7 enrolling by invitation. 7 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Enrolling by invitation 7 |
| Phase 2 | 1 | Enrolling by invitation 1 |
Follow Mental Disorders: new trials by email Literature Review of Mental Disorders trials Research Report on Mental Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of BRC-002 Safety, Tolerability, Pharmacokinetics, and Food Effects in Healthy Participants BRC-002, Placebo - Healthy Adult Participants | Phase 1 | Enrolling by invitation | Biopharmaceutical Research Company | 50 | 2026-06-15 | 2026-07-13 |
| Autism Spectrum Disorder (ASD) Neurodevelopmental Disorder With Issues Social Behavior, Communication Issues, GI Dysfunction. Study is Multimodal Interventions Targeting These Pathways With cSVF, Stored MSCs, FMT and Diet Modification. Role of Autoimmunity, Gut-brain Issues, & Issues Examined. Autologous MSC isolation, concentration, and cryopreservation of adult mesenchymal stem cells, Fecal Biomicrome Transplantation (FMT), Ketogenic RESET Diet Protocol - Autism Spectrum Disorder, Autism | Phase 1 / Phase 2 | Enrolling by invitation | Black Tie Medical, Inc. | 50 | 2026-04-30 | 2026-04-27 |
| To Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Food Effects of LY03021 in Healthy Chinese Subjects LY03021, placebo - Major Depressive Disorder | Phase 1 | Enrolling by invitation | Luye Pharma Group Ltd. | 98 | 2025-10-28 | 2026-01-27 |
| tFUS for Memory in mNCD and Healthy Adults Transcranial Focused Ultrasound - Mild Neurocognitive Disorder, Healthy Aging | Phase 1 | Enrolling by invitation | Medical University of South Carolina | 25 | 2025-03-30 | 2025-11-24 |
| Weighted Blankets for IUD Insertion 10-pound weighted lap-pad, blanket - Intra-uterine Device Placement | Phase 1 | Enrolling by invitation | Saint Luke's Health System | 54 | 2025-03-01 | 2025-05-13 |
| Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities Methylphenidate Oral Solution - Intellectual Disability, Fragile X Syndrome | Phase 1 | Enrolling by invitation | University of California, Davis | 68 | 2023-02-01 | 2025-12-15 |
| Nitrous Oxide- Suicidal Ideation Nitrous Oxide, Placebo gas - Major Depressive Disorder, Depression | Phase 1 | Enrolling by invitation | Washington University School of Medicine | 50 | 2018-10-30 | 2025-12-22 |
Depressive Disorder, Major (2) · Anxiety Disorders (1) · Attention Deficit Disorder with Hyperactivity (1) · Autism Spectrum Disorder (1) · Autistic Disorder (1) · Communication (1) · Depression (1) · Down Syndrome (1) · Fragile X Syndrome (1) · Intellectual Disability (1) · Intestinal Diseases (1) · Learning Disabilities (1) · Marijuana Abuse (1) · Mood Disorders (1) · Neurocognitive Disorders (1)
Behavior (2) · Depressive Disorder (2) · Nervous System Diseases (2) · Neurobehavioral Manifestations (2) · Neurodevelopmental Disorders (2) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Abnormalities, Multiple (1) · Attention Deficit and Disruptive Behavior Disorders (1) · Behavioral Symptoms (1) · Chemically-Induced Disorders (1) · Child Development Disorders, Pervasive (1) · Chromosome Disorders (1)
Anti-Inflammatory Agents (1) · Fecal Microbiota Transplantation (1) · Immunomodulation (1) · Methylphenidate (1) · Nitrous Oxide (1)
Biopharmaceutical Research Company (1) · Black Tie Medical, Inc. (1) · Luye Pharma Group Ltd. (1) · Medical University of South Carolina (1) · Saint Luke's Health System (1) · University of California, Davis (1) · Washington University School of Medicine (1)
United States (5) · Canada (1) · China (1)
Anna Guastello, BSN (1) · Charles R Conway, MD (1) · Kevin Caulfield, PhD (1)
R01HD076189 (1)